VIDEO: Tremfya safe, efficacious for moderately to severely active Crohn’s

SAN DIEGO — In this video exclusive, Remo Panaccione, MD, of the University of Calgary, discussed a study assessing the safety and efficacy of Tremfya in patients with moderately to severely active Crohn’s disease.During the GALAXI1, phase 2, double-blind, placebo-controlled, multicenter study, patients were randomly assigned to Tremfya (guselkumab, Janssen) dosed 200 mg, 600 mg or 1,200 mg intravenously, Stelara (ustekinumab, Janssen) dosed approximately 6 mg/kg intravenously to 90 mg subcutaneously, or intravenous placebo during the induction phase.The results, presented atRead More